| Kamakshi Vemareddy, MD | |
|
41 Brewster Rd # Leveld, Bristol, CT 06010-5161 | |
| (860) 585-3295 | |
| (860) 585-3375 |
| Full Name | Kamakshi Vemareddy |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 31 Years |
| Location | 41 Brewster Rd # Leveld, Bristol, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851588214 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 048472 (Connecticut) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bristol Hospital | Bristol, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bristol Hospital Multi-specialty Group, Inc. | 9032014758 | 114 |
News Archive
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
The portion of the brain responsible for visual reading doesn't require vision at all, according to a new study by researchers from the Hebrew University of Jerusalem and France.
Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology.
Evotec AG has announced that its Tools and Technologies Division has sold the core of its Single Molecule Detection Technology and transferred or licensed the corresponding IP portfolio to Olympus Corporation, Tokyo, Japan.
Doctors have long known that smell is one of the first senses to fail as Alzheimer's begins its slow and incurable progression. Tracking the process whereby a person loses their ability to smell could play a pivotal role in early detection and treatment of Alzheimer's. And now researchers at Columbia have developed a tool that will aid early detection.
› Verified 8 days ago
| Entity Name | Bristol Hospital Multi-specialty Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649265679 PECOS PAC ID: 9032014758 Enrollment ID: O20031204000960 |
News Archive
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
The portion of the brain responsible for visual reading doesn't require vision at all, according to a new study by researchers from the Hebrew University of Jerusalem and France.
Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology.
Evotec AG has announced that its Tools and Technologies Division has sold the core of its Single Molecule Detection Technology and transferred or licensed the corresponding IP portfolio to Olympus Corporation, Tokyo, Japan.
Doctors have long known that smell is one of the first senses to fail as Alzheimer's begins its slow and incurable progression. Tracking the process whereby a person loses their ability to smell could play a pivotal role in early detection and treatment of Alzheimer's. And now researchers at Columbia have developed a tool that will aid early detection.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kamakshi Vemareddy, MD Po Box 2828, Bristol, CT 06011-2828 Ph: (860) 585-3906 | Kamakshi Vemareddy, MD 41 Brewster Rd # Leveld, Bristol, CT 06010-5161 Ph: (860) 585-3295 |
News Archive
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
The portion of the brain responsible for visual reading doesn't require vision at all, according to a new study by researchers from the Hebrew University of Jerusalem and France.
Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology.
Evotec AG has announced that its Tools and Technologies Division has sold the core of its Single Molecule Detection Technology and transferred or licensed the corresponding IP portfolio to Olympus Corporation, Tokyo, Japan.
Doctors have long known that smell is one of the first senses to fail as Alzheimer's begins its slow and incurable progression. Tracking the process whereby a person loses their ability to smell could play a pivotal role in early detection and treatment of Alzheimer's. And now researchers at Columbia have developed a tool that will aid early detection.
› Verified 8 days ago
Dr. Julie Goldberg Malkin, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 277 West St, Bristol, CT 06010 Phone: 860-582-5515 Fax: 860-589-2467 | |
Mrs. Sharon Okin Adler, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 25 Newell Rd, Ste E 32, Bristol, CT 06010 Phone: 860-582-8074 Fax: 860-583-8107 | |
Dr. Stephanie Hammerich-hille, MD, PHD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 25 Newell Rd Ste E35, Bristol, CT 06010 Phone: 860-276-6800 Fax: 860-276-6801 | |
Minu Rowther, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 41 Brewster Rd # Leveld, Bristol, CT 06010 Phone: 860-585-3295 Fax: 860-585-3375 | |
Dr. Rupalini Rawal-dhingra, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 25 Newell Rd Ste E31, Bristol, CT 06010 Phone: 860-589-7762 Fax: 860-589-8132 | |
Victoria Biondi, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 25 Newell Rd, Suite D28, Bristol, CT 06010 Phone: 860-584-4240 Fax: 860-585-5852 | |
Dr. Kenneth Keonwooh Rhee, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 277 West Street, Suite B, Bristol, CT 06010 Phone: 860-589-7762 Fax: 860-589-8132 |